Celebrity Inventors
Mark Twain (Samuel L. Clemens) received Patent No. 121,992 for "An Improvement in Adjustable and Detachable Straps for Garments." He later received two more patents: one for a self-pasting scrapbook and one for a game to help players remember important historical dates.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8124776 | Process and intermediates for preparing arzoxifene The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of —CH2CH3 and phenyl; or R1 and R2 combin... | 02/28/2012 |
| 7655641 | Sulfonamide derivatives as PPAR modulators The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) s... | 02/02/2010 |
| 7608639 | Phenoxyether derivatives as PPAR modulators The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such... | 10/27/2009 |
| 7598266 | Fused heterocyclic derivatives as PPAR modulators The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)... | 10/06/2009 |
| 7585977 | Selective estrogen receptor modulators containing a phenylsulfonyl group The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata. ... | 09/08/2009 |
| 7544812 | Peroxisome proliferator activated receptor agonists The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-4-alk... | 06/09/2009 |
| 7544707 | Bicyclic derivatives as PPAR modulators The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C... | 06/09/2009 |
| 7507832 | Triazole PPAR modulators The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the... | 03/24/2009 |
| 7504433 | Thiophene derivative PPAR modulators The present invention is directed to compounds represented by the following structural formula, Formula I: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) X is selected from the group consisting of O, S, S(O)2, N, an... | 03/17/2009 |
| 7396850 | Pyrazole derivative as PPAR modulator The present invention is directed to a compound, {2-Methyl-4-[3-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid and pharmaceutical uses thereof. ... | 07/08/2008 |
| 7384965 | Fused heterocyclic derivatives as PPAR modulators The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U ia an aliphatic linker; (c) Y is selected from the gr... | 06/10/2008 |
| 7351728 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H... | 04/01/2008 |
| 7345070 | Peroxisome proliferator activated receptor agonists Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalk... | 03/18/2008 |
| 7321056 | Selective peroxisome proliferator activated receptor modulators The present invention is directed to a novel compound, its composition and use of a compound having a structural formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomers thereof, which is useful in treating or preventing disorders mediat... | 01/22/2008 |
| 7304062 | Peroxisome proliferator activated receptor alpha agonists The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C | 12/04/2007 |
| 7282501 | Modulators of peroxisome proliferator activated receptors (PPAR) The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hyperte... | 10/16/2007 |
| 7220880 | Amide linker peroxisome proliferator activated receptor modulators The present invention is directed to compounds, compositions, and use of compounds the structural Formula (I) ... | 05/22/2007 |
| 7205321 | Peroxisome proliferator activated receptor alpha agonists The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected fr... | 04/17/2007 |
| 7176224 | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and ... | 02/13/2007 |
| 7153878 | Peroxisome proliferator activated receptor modulators The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the group consisting of (C1–C6)alkyl, (C | 12/26/2006 |
| 7122203 | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof The present invention is directed to pharmaceutical formulations containing 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxypheny)benzo[b]thiophene or a salt thereof; stabilized to oxidation or other forms of decomposition by incorporation of a stabili... | 10/17/2006 |
| 6992097 | Growth hormone secretagogues This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in thes... | 01/31/2006 |
| 5643926 | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastri... | 07/01/1997 |
| 5470978 | Process and intermediates for the preparation of excitatory amino acid receptor antagonists The present invention provides novel intermediates which are useful for the preparation of excitatory amino acid receptor antagonists. Further provided is a process to enatioselectively prepare hydroisoquinoline compounds with central nervous system activ... | 11/28/1995 |
| 5434171 | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates This invention relates to a process for preparing certain 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates, intermediates, and congeners. Finally, the invention provides new 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates with formulations and ... | 07/18/1995 |
| 5389684 | Naphthalene carboxamides Pharmaceutical compounds of the formula: ##STR1## in which each R1 is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen or nitro, and n is 0, 1, 2 or 3, R2 is hydrogen, C1-4 alkyl or C2-4 alk... | 02/14/1995 |
